Tianjin Jianfeng Flanders Company "changed!
Release time:
2020-07-22
Tianjin Jianfeng Flanders Company "changed to " !
News 4# November 22 , Tianjin Jianfeng Flanders Company received the "Food Production License" issued by Tianjin Binhai New Area Market and Quality Supervision Administration Bureau, including candy products and beverages. In the future, Flanders will transform into a R & D and production enterprise of nutritional molecular functional food, ushering in a broader market and new development opportunities.
For a long time, Flanders's main business has been pharmaceutical excipients pellets and coating powder. With the continuous decline of the profit margin of the pharmaceutical excipients market, the development of the enterprise has also encountered bottlenecks, and it is urgent to adjust the development thinking. Under the background of the current national development of a large health industry, Flanders has conducted in-depth research on the new food market, and determined to use its own R & D advantages and the accumulation of new food formulas to focus its work on R & D and production of functional foods. The strategic shift has received strong support from the leaders of the group and the pharmaceutical industry. For this reason, Jianfeng Flanders Company began to prepare to apply for the "Food Production License" at the beginning of 2019 . On the basis of the completion of the transformation of the production workshop and laboratory, it also made more detailed transformation to the various functions of the workshop according to the special requirements of food production, and purchased necessary production equipment and testing instruments. All employees also actively studied and implemented various examination rules, according to the functional food research and development, production related standards completed the software construction. 4 9 , in accordance with the requirements of the "General Rules for Examination of Food Production License", "Detailed Rules for Examination of Production License for Beverage (Solid Beverage) and Candy (Tablet Candy) Products" and Tianjin Market Supervision Law [2015 ] 20 , Tianjin Food Examination Center sent personnel to conduct on-site examination of food production license of Jianfeng Flanders Company. Finally, the on-site verification was passed with a score of 92 (out of 97 ).
Nutritional molecular functional food, that is, considering the formula design from the perspective of the nutrition required by the human body, determining the correlation between ingredients and human body functions at the molecular level, looking for a breakthrough from the perspective of food functions, and determining product differences. In the next three years, Flanders will focus on the research and development of nutritional molecular functional foods, establish and develop brands, build a high-level R & D system, comprehensively carry out technological innovation and intellectual property strategies, and establish new talent development and Internet strategies. Support, integrate new businesses into the global industrial chain and serve more sub-health people. Based on the technological achievements accumulated over the years, Flanders has identified a number of series of nutritional molecular functional foods, and the first batch will launch a series of confectionery and beverage products with plant ingredient formula and amino acid compound and added in the form of pellets. At present, excellent customer teams have come to discuss cooperation. (Liu Hairong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page